CRSP FY2025 EPS Lifted by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Management increased their FY2025 earnings per share estimates for CRISPR Therapeutics in a research report issued on Monday, November 10th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($4.76) per share for the year, up from their prior estimate of ($6.45). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million.

Several other research analysts have also commented on CRSP. Royal Bank Of Canada lifted their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Robert W. Baird reduced their price target on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday. Needham & Company LLC cut their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a research report on Monday, October 13th. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $67.84.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $1.06 during midday trading on Thursday, hitting $51.13. The company had a trading volume of 391,451 shares, compared to its average volume of 2,549,014. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $78.48. The company has a 50 day moving average of $63.02 and a 200 day moving average of $53.44. The stock has a market capitalization of $4.87 billion, a P/E ratio of -9.17 and a beta of 1.89.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRSP. SVB Wealth LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter worth approximately $25,000. Costello Asset Management INC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new position in shares of CRISPR Therapeutics in the 2nd quarter worth $33,000. Thompson Investment Management Inc. purchased a new position in CRISPR Therapeutics during the 3rd quarter worth $33,000. Finally, Optiver Holding B.V. grew its position in CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel owned 83,402 shares in the company, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 56,213 shares of company stock valued at $3,810,458. Insiders own 4.30% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.